Top

Published in:

01-09-2014 | Original Article

Mosaic partial deletion of the PTEN gene in a patient with Cowden syndrome

Authors: Erin E. Salo-Mullen, Jinru Shia, Isaac Brownell, Peter Allen, Monica Girotra, Mark E. Robson, Kenneth Offit, Jose G. Guillem, Arnold J. Markowitz, Zsofia K. Stadler

Published in: Familial Cancer | Issue 3/2014

Abstract

Cowden syndrome is an autosomal dominant condition caused by pathogenic mutations in the phosphatase and tensin homolog (PTEN) gene. Only a small proportion of identified pathogenic mutations have been reported to be large deletions and rearrangements. We report on a female patient with a previous history of breast ductal carcinoma in situ who presented to our institution for management of gastrointestinal hamartomatous polyposis. Although several neoplastic predisposition syndromes were considered, genetic evaluation determined that the patient met clinical diagnostic criteria for Cowden syndrome. Array-based comparative genomic hybridization was performed and revealed a mosaic partial deletion of the PTEN gene. Follow-up clinical history including bilateral thyroid nodules, dermatological findings, and a new primary “triple-negative” adenocarcinoma of the contralateral breast are discussed. We highlight the need for recognition and awareness of mosaicism as it may provide an explanation for variable phenotypic presentations and may alter the genetic counseling risk assessment of affected individuals and family members.

Nelen MR, Padberg GW, Peeters EA et al (1996) Localization of the gene for Cowden disease to chromosome 10q22-23. Nat Genet 13(1):114–116. doi:10.1038/ng0596-114 PubMedCrossRef

Liaw D, Marsh DJ, Li J et al (1997) Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 16(1):64–67. doi:10.1038/ng0597-64 PubMedCrossRef

Nelen MR, van Staveren WC, Peeters EA et al (1997) Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum Mol Genet 6(8):1383–1387PubMedCrossRef

Mester J, Eng C (2012) Estimate of de novo mutation frequency in probands with PTEN hamartoma tumor syndrome. Genet Med Off J Am Coll Med Genet 14(9):819–822. doi:10.1038/gim.2012.51

Nelen MR, Kremer H, Konings IB et al (1999) Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype correlations. European journal of human genetics EJHG 7(3):267–273. doi:10.1038/sj.ejhg.5200289 PubMedCrossRef

Eng C (2000) Will the real Cowden syndrome please stand up: revised diagnostic criteria. J Med Genet 37(11):828–830PubMedPubMedCentralCrossRef

Haibach H, Burns TW, Carlson HE, Burman KD, Deftos LJ (1992) Multiple hamartoma syndrome (Cowden’s disease) associated with renal cell carcinoma and primary neuroendocrine carcinoma of the skin (Merkel cell carcinoma). Am J Clin Pathol 97(5):705–712PubMed

Schrager CA, Schneider D, Gruener AC, Tsou HC, Peacocke M (1998) Clinical and pathological features of breast disease in Cowden’s syndrome: an underrecognized syndrome with an increased risk of breast cancer. Hum Pathol 29(1):47–53PubMedCrossRef

Zbuk KM, Eng C (2007) Cancer phenomics: rET and PTEN as illustrative models. Nat Rev Cancer 7(1):35–45. doi:10.1038/nrc2037 PubMedCrossRef

10.

Pilarski R, Burt R, Kohlman W, Pho L, Shannon KM, Swisher E (2013) Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria. J Natl Cancer Inst 105(21):1607–1616. doi:10.1093/jnci/djt277 PubMedCrossRef

11.

National comprehensive cancer network. Genetic/familial high-risk assessment: breast and ovarian. (Version 1.2013). http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf. Accessed 9 April 2013

12.

Marsh DJ, Coulon V, Lunetta KL et al (1998) Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet 7(3):507–515PubMedCrossRef

13.

Zhou XP, Waite KA, Pilarski R et al (2003) Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/Akt pathway. Am J Hum Genet 73(2):404–411. doi:10.1086/377109 PubMedPubMedCentralCrossRef

14.

Chibon F, Primois C, Bressieux JM et al (2008) Contribution of PTEN large rearrangements in Cowden disease: a multiplex amplifiable probe hybridisation (MAPH) screening approach. J Med Genet 45(10):657–665. doi:10.1136/jmg.2008.058131 PubMedCrossRef

15.

Lachlan KL, Lucassen AM, Bunyan D, Temple IK (2007) Cowden syndrome and Bannayan Riley Ruvalcaba syndrome represent one condition with variable expression and age-related penetrance: results of a clinical study of PTEN mutation carriers. J Med Genet 44(9):579–585. doi:10.1136/jmg.2007.049981 PubMedPubMedCentralCrossRef

16.

Orloff MS, Eng C (2008) Genetic and phenotypic heterogeneity in the PTEN hamartoma tumour syndrome. Oncogene 27(41):5387–5397. doi:10.1038/onc.2008.237 PubMedCrossRef

17.

Tan MH, Mester J, Peterson C et al (2011) A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands. Am J Hum Genet 88(1):42–56. doi:10.1016/j.ajhg.2010.11.013 PubMedPubMedCentralCrossRef

18.

Bubien V, Bonnet F, Brouste V et al (2013) High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. J Med Genet 50(4):255–263. doi:10.1136/jmedgenet-2012-101339 PubMedCrossRef

19.

Gammon A, Jasperson K, Pilarski R, Prior T, Kuwada S (2012) PTEN mosaicism with features of Cowden syndrome. Clin Genet. doi:10.1111/cge.12078

20.

Pritchard CC, Smith C, Marushchak T et al (2013) A mosaic PTEN mutation causing Cowden syndrome identified by deep sequencing. Genet Med Off J Am Coll Med Genet. doi:10.1038/gim.2013.51

21.

Gottlieb B, Beitel LK, Trifiro MA (2001) Somatic mosaicism and variable expressivity. Trends Genet TIG 17(2):79–82CrossRef

22.

Youssoufian H, Pyeritz RE (2002) Mechanisms and consequences of somatic mosaicism in humans. Nat Rev Genet 3(10):748–758. doi:10.1038/nrg906 PubMedCrossRef

23.

Kluwe L, Mautner V, Heinrich B et al (2003) Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas. J Med Genet 40(2):109–114PubMedPubMedCentralCrossRef

24.

Moyhuddin A, Baser ME, Watson C et al (2003) Somatic mosaicism in neurofibromatosis 2: prevalence and risk of disease transmission to offspring. J Med Genet 40(6):459–463PubMedPubMedCentralCrossRef

25.

Evans DG, Ramsden RT, Shenton A et al (2007) Mosaicism in neurofibromatosis type 2: an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification. J Med Genet 44(7):424–428. doi:10.1136/jmg.2006.047753 PubMedPubMedCentralCrossRef

26.

Evans DG, Wallace AJ, Wu CL, Trueman L, Ramsden RT, Strachan T (1998) Somatic mosaicism: a common cause of classic disease in tumor-prone syndromes? Lessons from type 2 neurofibromatosis. Am J Hum Genet 63(3):727–736. doi:10.1086/512074 PubMedPubMedCentral

27.

Hes FJ, Nielsen M, Bik EC et al (2008) Somatic APC mosaicism: an underestimated cause of polyposis coli. Gut 57(1):71–76. doi:10.1136/gut.2006.117796 PubMedCrossRef

28.

Santarpia L, Sarlis NJ, Santarpia M, Sherman SI, Trimarchi F, Benvenga S (2007) Mosaicism in von Hippel-Lindau disease: an event important to recognize. J Cell Mol Med 11(6):1408–1415. doi:10.1111/j.1582-4934.2007.00122.x PubMedCrossRef

29.

Murgia A, Martella M, Vinanzi C, Polli R, Perilongo G, Opocher G (2000) Somatic mosaicism in von Hippel-Lindau Disease. Hum Mutat 15(1):114. doi:10.1002/(sici)1098-1004(200001)15:1<114:aid-humu20>3.0.co;2-7 PubMedCrossRef

30.

Prochazkova K, Pavlikova K, Minarik M, Sumerauer D, Kodet R, Sedlacek Z (2009) Somatic TP53 mutation mosaicism in a patient with Li-Fraumeni syndrome. Am J Med Genet Part A 149A(2):206–211. doi:10.1002/ajmg.a.32574 PubMedCrossRef

31.

Gripp KW, Stabley DL, Nicholson L, Hoffman JD, Sol-Church K (2006) Somatic mosaicism for an HRAS mutation causes Costello syndrome. Am J Med Genet Part A 140(20):2163–2169. doi:10.1002/ajmg.a.31456 PubMedCrossRef

32.

Upadhyaya M, Han S, Consoli C et al (2004) Characterization of the somatic mutational spectrum of the neurofibromatosis type 1 (NF1) gene in neurofibromatosis patients with benign and malignant tumors. Hum Mutat 23(2):134–146. doi:10.1002/humu.10305 PubMedCrossRef

33.

Rasmussen SA, Colman SD, Ho VT et al (1998) Constitutional and mosaic large NF1 gene deletions in neurofibromatosis type 1. J Med Genet 35(6):468–471PubMedPubMedCentralCrossRef

34.

Messiaen L, Vogt J, Bengesser K et al (2011) Mosaic type-1 NF1 microdeletions as a cause of both generalized and segmental neurofibromatosis type-1 (NF1). Hum Mutat 32(2):213–219. doi:10.1002/humu.21418 PubMedCrossRef

35.

Ainsworth PJ, Chakraborty PK, Weksberg R (1997) Example of somatic mosaicism in a series of de novo neurofibromatosis type 1 cases due to a maternally derived deletion. Hum Mutat 9(5):452–457. doi:10.1002/(sici)1098-1004(1997)9:5<452:aid-humu12>3.0.co;2-1 PubMedCrossRef

36.

Verhoef S, Bakker L, Tempelaars AM et al (1999) High rate of mosaicism in tuberous sclerosis complex. Am J Hum Genet 64(6):1632–1637. doi:10.1086/302412 PubMedPubMedCentralCrossRef

37.

Rushlow D, Piovesan B, Zhang K et al (2009) Detection of mosaic RB1 mutations in families with retinoblastoma. Hum Mutat 30(5):842–851. doi:10.1002/humu.20940 PubMedCrossRef

38.

Sippel KC, Fraioli RE, Smith GD et al (1998) Frequency of somatic and germ-line mosaicism in retinoblastoma: implications for genetic counseling. Am J Hum Genet 62(3):610–619. doi:10.1086/301766 PubMedPubMedCentralCrossRef

39.

Robberecht C, Fryns JP, Vermeesch JR (2010) Piecing together the problems in diagnosing low-level chromosomal mosaicism. Genome Med 2(7):47. doi:10.1186/gm168 PubMedPubMedCentralCrossRef

40.

Dumanski JP, Piotrowski A (2012) Structural genetic variation in the context of somatic mosaicism. Methods Mol Biol (Clifton, NJ) 838:249–272. doi:10.1007/978-1-61779-507-7_12 CrossRef

41.

Brownstein MH, Wolf M, Bikowski JB (1978) Cowden’s disease: a cutaneous marker of breast cancer. Cancer 41(6):2393–2398PubMedCrossRef

42.

Starink TM, van der Veen JP, Arwert F et al (1986) The Cowden syndrome: a clinical and genetic study in 21 patients. Clin Genet 29(3):222–233PubMedCrossRef

43.

Pilarski R (2009) Cowden syndrome: a critical review of the clinical literature. J Genet Couns 18(1):13–27. doi:10.1007/s10897-008-9187-7 PubMedCrossRef

44.

Saal LH, Gruvberger-Saal SK, Persson C et al (2008) Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet 40(1):102–107. doi:10.1038/ng.2007.39 PubMedPubMedCentralCrossRef

45.

Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61–70. doi:10.1038/nature11412 CrossRef

46.

Carlson GJ, Nivatvongs S, Snover DC (1984) Colorectal polyps in Cowden’s disease (multiple hamartoma syndrome). Am J Surg Pathol 8(10):763–770PubMedCrossRef

47.

Marra G, Armelao F, Vecchio FM, Percesepe A, Anti M (1994) Cowden’s disease with extensive gastrointestinal polyposis. J Clin Gastroenterol 18(1):42–47PubMedCrossRef

48.

Merg A, Howe JR (2004) Genetic conditions associated with intestinal juvenile polyps. Am J Med Genet Part C Semin Med Genet 129C(1):44–55. doi:10.1002/ajmg.c.30020 PubMedCrossRef

49.

Lashner BA, Riddell RH, Winans CS (1986) Ganglioneuromatosis of the colon and extensive glycogenic acanthosis in Cowden’s disease. Dig Dis Sci 31(2):213–216PubMedCrossRef

50.

Heald B, Mester J, Rybicki L, Orloff MS, Burke CA, Eng C (2010) Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers. Gastroenterology 139(6):1927–1933. doi:10.1053/j.gastro.2010.06.061 PubMedPubMedCentralCrossRef

51.

Brownstein MH, Mehregan AH, Bilowski JB (1977) Trichilemmomas in Cowden’s disease. JAMA J Am Med Assoc 238(1):26CrossRef

52.

Brownstein MH, Mehregan AH, Bikowski JB, Lupulescu A, Patterson JC (1979) The dermatopathology of Cowden’s syndrome. Br J Dermatol 100(6):667–673PubMedCrossRef

53.

Salem OS, Steck WD (1983) Cowden’s disease (multiple hamartoma and neoplasia syndrome). A case report and review of the English literature. J Am Acad Dermatol 8(5):686–696PubMedCrossRef

54.

Hanssen AM, Werquin H, Suys E, Fryns JP (1993) Cowden syndrome: report of a large family with macrocephaly and increased severity of signs in subsequent generations. Clin Genet 44(6):281–286PubMedCrossRef

55.

Hanssen AM, Fryns JP (1995) Cowden syndrome. J Med Genet 32(2):117–119PubMedPubMedCentralCrossRef

56.

Perren A, Komminoth P, Saremaslani P et al (2000) Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am J Pathol 157(4):1097–1103. doi:10.1016/s0002-9440(10)64624-x PubMedPubMedCentralCrossRef

57.

Zhou XP, Marsh DJ, Hampel H, Mulliken JB, Gimm O, Eng C (2000) Germline and germline mosaic PTEN mutations associated with a Proteus-like syndrome of hemihypertrophy, lower limb asymmetry, arteriovenous malformations and lipomatosis. Hum Mol Genet 9(5):765–768PubMedCrossRef

58.

Zhou X, Hampel H, Thiele H et al (2001) Association of germline mutation in the PTEN tumour suppressor gene and Proteus and Proteus-like syndromes. Lancet 358(9277):210–211PubMedCrossRef

59.

Caux F, Plauchu H, Chibon F et al (2007) Segmental overgrowth, lipomatosis, arteriovenous malformation and epidermal nevus (SOLAMEN) syndrome is related to mosaic PTEN nullizygosity. Eur J Hum Genet EJHG 15(7):767–773. doi:10.1038/sj.ejhg.5201823 CrossRef

Title: Mosaic partial deletion of the PTEN gene in a patient with Cowden syndrome
Authors: Erin E. Salo-Mullen
Jinru Shia
Isaac Brownell
Peter Allen
Monica Girotra
Mark E. Robson
Kenneth Offit
Jose G. Guillem
Arnold J. Markowitz
Zsofia K. Stadler
Publication date: 01-09-2014
Publisher: Springer Netherlands
Published in: Familial Cancer / Issue 3/2014
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI: https://doi.org/10.1007/s10689-014-9709-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2014

BRCA1 founder mutations compared to ovarian cancer in Belarus

Erratum to: Frequency of 5382insC mutation of BRCA1 gene among breast cancer patients: an experience from Eastern India

Two Chinese pedigrees for adenomatous polyposis coli: new mutations at codon 1309 and predisposition to phenotypic variations

A survey of the practice patterns of gynecologic oncologists dealing with hereditary cancer patients in Japan

Intronic splicing mutations in PTCH1 cause Gorlin syndrome

BRCA1 point mutations in premenopausal breast cancer patients from Central Sudan

Keynote webinar | Spotlight on antibody–drug conjugates in cancer